A Phase II, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of 12 Weeks of Treatment With ARRY-371797 in Patients With Active Ankylosing Spondylitis and Inadequate Response to Conventional Therapy.

Trial Profile

A Phase II, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of 12 Weeks of Treatment With ARRY-371797 in Patients With Active Ankylosing Spondylitis and Inadequate Response to Conventional Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2012

At a glance

  • Drugs ARRY 797 (Primary)
  • Indications Ankylosing spondylitis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 02 Mar 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 10 Jul 2009 Planned number of patients changed from 168 to 25 as reported by ClinicalTrials.gov.
    • 10 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top